Selecta Biosciences, Inc. Receives 2012 Edison Award’s Gold Medal for Best Pharmaceutical Product Innovation

WATERTOWN, Mass.--(BUSINESS WIRE)--Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company developing a new class of synthetic vaccines and immunotherapies, today announced that it has received the prestigious Edison Award for 2012 with the Gold Medal for Best Pharmaceutical Product Innovation. This award recognizes Selecta’s novel platform that enables an entirely new way to develop therapeutic and prophylactic vaccines that are highly targeted for improved efficacy and safety. The Edison Awards symbolize the persistence and excellence personified by Thomas Alva Edison, inspiring America’s drive to remain in the forefront of innovation, creativity and ingenuity in the global economy.

Back to news